There is a specific group of people for whom this number means something immediately: the 626,000 Medicare Part D enrollees who filled a Breo Ellipta prescription in a single year, most of them managing COPD or asthma. Starting January 1, 2027, Medicare’s negotiated price for a 30-day supply of that inhaler is $67. The 2024 list price was $397.
Two GSK inhalers, and the distance between $397 and $67
Breo Ellipta is not the only respiratory drug in this round. Trelegy Ellipta, made by the same company and prescribed for the same two conditions, goes to $175 a month against a 2024 list price of $654. Trelegy was the more widely used of the two, dispensed to 1,269,000 Part D enrollees in 2024 against Breo’s 626,000, which puts the respiratory cohort among the largest groups touched by this round of negotiated prices.
The percentages are steep. Breo’s negotiated price is an 83 percent discount off that 2024 list price, and Trelegy’s is 73 percent. But read the words “list price” carefully, because they are doing real work. The CMS fact sheet carrying these figures notes that the list prices shown are Wholesale Acquisition Costs based on 2024 fills. That is a manufacturer’s sticker number, not a description of what any particular person handed the pharmacist. Nobody with drug coverage was paying $397 a month for Breo Ellipta out of their own pocket.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
A negotiated price is the pharmacy counter’s price, not automatically your copay
Here is the mechanic that decides whether $67 shows up in your life. The negotiated price, which the law calls a maximum fair price, is the price the drug company must make available to eligible Medicare enrollees and to the pharmacies, mail-order services and other entities that dispense the drug. It governs the transaction. It does not, by itself, dictate what your particular plan charges you at the register.
Whether the drop reaches you depends on how your plan structures cost sharing for that drug. Under Medicare’s defined standard benefit, once you clear the deductible you pay 25 percent of the cost of a covered drug as coinsurance until your out-of-pocket spending hits the annual cap, after which you pay nothing more for covered drugs that year. Medicare’s page on drug coverage costs lays out those stages, using 2026’s figures of a $615 maximum deductible and a $2,100 out-of-pocket cap. If your share is a percentage, a lower underlying price mechanically lowers your share. If your plan instead charges a flat copay for the tier that drug sits on, the copay is a number your plan set, and it does not automatically move when the price behind it moves.
Where CMS says the $685 million actually lands
CMS put a figure on the household side of this. When the negotiated prices take effect in 2027, people with Medicare drug coverage “would save under the defined standard benefit design an estimated $685 million in out-of-pocket costs.” Note the qualifier the agency attached: defined standard benefit design. That is the government’s model benefit, the one where cost sharing is a percentage of the price.
For context on the pool that money is spread across, 5.3 million of the 53 million people with Part D coverage were dispensed at least one of the 15 selected drugs during 2024, and together they spent $1.7 billion out of pocket on them. There is also a wrinkle worth understanding if your drug spending is heavy. Because Part D now stops charging you once your out-of-pocket total reaches the annual limit, a lower price on one drug changes how quickly you reach that ceiling more than it changes what you spend across the full year. The people most likely to feel the $67 directly are those whose yearly drug spending lands below the cap, where every reduction is money that stays in the account.
Your plan is required by law to carry these drugs
One question that follows any price cut is whether an insurer can simply drop the drug and route you to something else. On this list, it cannot. CMS states that Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage plans with drug coverage, must include the selected drugs with agreed negotiated prices in their formularies, and that the agency will use its formulary review process to assess practices that may undermine access.
Coverage is not the same as favorable placement, which is why tier assignment is the thing to check on your own plan rather than assume. CMS maintains the running record on its selected drugs and negotiated prices page, including a published explanation file for Breo Ellipta specifically, showing how the maximum fair price applies across the drug’s dosage forms and strengths.
Settled in 2025, effective in 2027, and no part of it is new this month
The timeline matters because it keeps getting garbled. These prices were not announced this summer. The second round of Medicare drug price negotiation ran through 2025, the negotiation period closed on November 1, 2025, and CMS published the agreed prices for all 15 drugs that month. Nothing has been renegotiated since. What happens on January 1 is not an announcement, it is an effective date.
After that first year, each negotiated price is updated annually by the change in the Consumer Price Index for all urban consumers, so $67 is a starting point rather than a permanent figure. The piece still missing is plan-level: where your specific plan places Breo Ellipta on its formulary and what it charges for that tier. Those details arrive with the rest of next year’s offerings, which CMS says it will publish with the 2027 Medicare Advantage and Part D landscape in mid-to-late September. Until then, the fixed points are the ones CMS has already published: $67 for a 30-day supply, effective January 1, against a $397 list price and 626,000 Part D users in a single year.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
